NASDAQ · SONM

DNA X, Inc.

$3.19 +$0.04 (+1.24%) 1D Market open

Key Metrics

$4.69M
Market cap
0.80×
P/E · TTM
Revenue · TTM
$5.88M
Net income
EPS · TTM $18.13
Dividend yield
Free cash flow
Beta · 1Y 0.64
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 2
    The stock moved -28.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 2
  • Jun 2
    The stock moved +22.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 2
  • Mar 26
    From its Feb 10 high, the share price fell 61%.

    Peak close $7.01 on Feb 10; trough close $2.75 on Mar 26. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -61%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.69M
Enterprise value$5.64M
Shares outstanding1.5M
52-wk range$2.62 – $16.97
Avg volume · 20D22.1K
Net cash −$949.00K
Book value / share$-3.03
IndustryTelephone & Telegraph Apparatus
ExchangeNASDAQ
About DNA X, Inc.
IPO dateMay 10, 2019
Employees4

DNA X Inc is engaged in providing crypto trading services through its online platform, enabling users to buy, sell, and exchange cryptocurrencies, as well as execute automated trading strategies between currency pairs. The company generates revenue from commissions and fees on trading activity.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E0.80
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -598.4% · —

Financial Health

Current ratio0.76
Quick ratio
Debt / equity-2.18
Debt / EBITDA
Net cash −$949.00K
Working capital−$1.02M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings